Clovis Oncology, Inc. CLVS today announced the presentation of data from the Phase 3 TRITON3 study in men with metastatic castration-resistant prostate cancer harboring BRCA or ATM mutations. The presentation, titled “TRITON3: A Phase 3 Study of Rucaparib vs. Physician’s Choice of Therapy in mCRPC Associated with Homologous Recombination Deficiency (HRD)” will be presented by Alan H. Bryce, MD, Chair of the Division of Hematology and Medical Oncology at the Mayo Clinic and Co-Principal Investigator of the TRITON3 Trial during the session titled “Novel Clinical Trial Updates” on March 29thth Annual Prostate Cancer Foundation (PCF) Scientific Retreat.
The presentation is available at https://clovisoncology.com/pipeline/scientific-presentations/.
“We believe the positive results from TRITON3 demonstrate the important role Rubraca could play as a treatment option for men with metastatic castration-resistant prostate cancer associated with a lack of homologous recombination. This is the first and only PARP inhibitor to be shown radiologically to have superior PFS compared to a control arm containing docetaxel chemotherapy, which is now the standard of care for these patients,” said Patrick J. Mahaffy, President and CEO from Clovis Oncology, “We look forward to providing additional data for presentation at a medical meeting in 2023.”
Earlier this month, the company reported top-line data from the TRITON3 (NCT02975934) study evaluating Rubraca monotherapy versus chemotherapy or a second-line androgen pathway inhibitor in patients with chemotherapy-naïve mCRPC with mutations in BRCA or ATM met the primary endpoint of improved radiographic progression-free survival (rPFS). an independent radiological review (IRR).
About the TRITON3 clinical study
TRITON3 (NCT02975934) is a multicenter, open-label, randomized, phase 3 study of Rubraca in patients with chemotherapy-naïve mCRPC. Patients with a mutation in BRCA or ATM were randomized…
